Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma

Bibliographic Details
Main Authors:	Mueller, G, Vanderkerken, K, Russell, R, Croucher, P
Format:	Conference item
Published:	2004

Similar Items

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
by: Mueller, G, et al.
Published: (2004)

The Role of Myeloma Cells to Osteoclast Activation
by: Bahare Sadeghi, et al.
Published: (2010-01-01)

Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease
by: Ersek, A, et al.
Published: (2015)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

An In Vitro Model of Murine Osteoclast-Mediated Bone Resorption
by: Xiaoyue Sun, et al.
Published: (2024-11-01)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
by: Edwards, C, et al.
Published: (2007)

Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
by: Leng, H
Published: (2019)

Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
by: Mabilleau, G, et al.
Published: (2009)

Interleukin-32 promotes osteoclast differentiation but not osteoclast activation.
by: Mabilleau, G, et al.
Published: (2009)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
by: Croucher, P, et al.
Published: (2002)

Osteoprotegerin and the development of myeloma bone disease
by: Croucher, P, et al.
Published: (2004)

Zoledronic Acid Inhibits the Capacity of Myeloid-Immune Suppressor Cells in Myeloma to Form Osteoclasts.
by: Zhuang, J, et al.
Published: (2008)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
by: Dongzheng Gai, et al.
Published: (2022-09-01)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
by: Yu-Tzu Tai, et al.
Published: (2018-08-01)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
by: Tibullo eDaniele, et al.
Published: (2015-10-01)

Bisphosphonates and in vivo models of multiple myeloma - Reply
by: Shipman, C, et al.
Published: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
by: Croucher, P, et al.
Published: (2000)

Bisphosphonates--mechanisms of action in multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease
by: Jing Fu, et al.
Published: (2023-07-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
by: Croucher, P, et al.
Published: (2003)

BISPHOSPHONATES AFFECT HUMAN OSTEOCLAST DEVELOPMENT IN VITRO
by: Mabilleau, G, et al.
Published: (2010)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
by: Vanderkerken, K, et al.
Published: (2003)

Osteoclasts in myeloma are derived from Gr-1+CD11b+mononuclear cells of the bone marrow niche
by: Zhuang, J, et al.
Published: (2007)

Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells
by: Zhuang, J, et al.
Published: (2012)

Glucose Ceramide Synthase Inhibitors Inhibit Osteoclast Activation Induced by Myeloma-Derived and De Novo Synthesized Glycosphingolipids
by: Xu, K, et al.
Published: (2009)

Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts.
by: Minna Qiao, et al.
Published: (2015-01-01)

A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.
by: Maiko Matsushita, et al.
Published: (2015-01-01)

In vitro generation of mature human osteoclasts.
by: Hemingway, F, et al.
Published: (2011)

In vitro generation of mature human osteoclasts.
by: Hemingway, F, et al.
Published: (2011)

Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts.
by: Kudo, O, et al.
Published: (2002)

Effect of amorphous silica nanoparticles on <it>in vitro </it>RANKL-induced osteoclast differentiation in murine macrophages
by: Nagano Kazuya, et al.
Published: (2011-01-01)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
by: Liesbeth Bieghs, et al.
Published: (2010-01-01)

Osteoclasts and Microgravity
by: John Kelly Smith
Published: (2020-09-01)

Estrogen receptor gene expression in osteoclasts loss with osteoclast maturation.
by: Oreffo, R, et al.
Published: (1997)

Osteoclast Activation and Inflammatory Bone Diseases: Focusing on Receptors in Osteoclasts
by: Zhao W, et al.
Published: (2025-03-01)

NK cells support osteoclast formation in vitro
by: Owen, S, et al.
Published: (2004)

Activated T lymphocytes support osteoclast formation in vitro.
by: Horwood, N, et al.
Published: (1999)

NK cells support osteoclast formation in vitro
by: Danks, L, et al.
Published: (2005)

The effects of seeding density and osteoclastic supplement concentration on osteoclastic differentiation and resorption
by: Stefan J.A. Remmers, et al.
Published: (2023-06-01)

Ewing's sarcoma cells promote osteoclast formation
by: Taylor, R, et al.
Published: (2010)